During the last session, Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)’s traded shares were 0.49 million, with the beta value of the company hitting -0.38. At the end of the trading day, the stock’s price was $328.14, reflecting an intraday loss of -3.53% or -$12.0. The 52-week high for the MDGL share is $368.29, that puts it down -12.24 from that peak though still a striking 48.73% gain since the share price plummeted to a 52-week low of $168.25. The company’s market capitalization is $7.16B, and the average intraday trading volume over the past 10 days was 0.62 million shares, and the average trade volume was 477.25K shares over the past three months.
Madrigal Pharmaceuticals Inc (MDGL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.44. MDGL has a Sell rating from 0 analyst(s) out of 11 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 9 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -4.24.
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) trade information
Madrigal Pharmaceuticals Inc (MDGL) registered a -3.53% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.53% in intraday trading to $328.14, hitting a weekly high. The stock’s 5-day price performance is 20.29%, and it has moved by 6.39% in 30 days. Based on these gigs, the overall price performance for the year is 43.29%. The short interest in Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) is 4.11 million shares and it means that shorts have 13.08 day(s) to cover.
The consensus price target of analysts on Wall Street is $355.5, which implies an increase of 7.7% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $111 and $410 respectively. As a result, MDGL is trading at a discount of -24.95% off the target high and 66.17% off the low.
Madrigal Pharmaceuticals Inc (MDGL) estimates and forecasts
Statistics show that Madrigal Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Madrigal Pharmaceuticals Inc (MDGL) shares have gone up 16.34% during the last six months, with a year-to-date growth rate less than the industry average at -17.81% against 16.80.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 94.65M as predicted by 14 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 104.14M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -55.24%. While earnings are projected to return -17.91% in 2025.
MDGL Dividends
Madrigal Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)’s Major holders
Madrigal Pharmaceuticals Inc insiders own 8.55% of total outstanding shares while institutional holders control 105.95%, with the float percentage being 115.86%. JANUS HENDERSON GROUP PLC is the largest shareholder of the company, while 351.0 institutions own stock in it. As of 2024-06-30, the company held over 2.49 million shares (or 12.4278% of all shares), a total value of $696.33 million in shares.
The next largest institutional holding, with 2.06 million shares, is of AVORO CAPITAL ADVISORS LLC’s that is approximately 10.277% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $575.88 million.
Also, the Mutual Funds coming in first place with the largest holdings of Madrigal Pharmaceuticals Inc (MDGL) shares are Vanguard Total Stock Market Index Fund and Janus Henderson Forty Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 578.71 shares. This amounts to just over 2.65 percent of the company’s overall shares, with a $189.9 million market value. The same data shows that the other fund manager holds slightly less at 565.93, or about 2.59% of the stock, which is worth about $185.7 million.
